Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.

Becton Dickinson shares hit record high after US FDA clears return of drug infusion system

The company filed a 501(k) resubmission for its new BD Alaris Infusion System two years ago. The company said it will begin immediately distributing the new Alaris Infusion System, and will remediate older versions of the device.

Why Shares of Becton, Dickinson Rose Monday

FRANKLIN LAKES, N.J. , July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the updated BD Alaris™ Infusion System: "Hello, I'm Tom Polen, chairman, CEO and president of BD.

BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring, auto-identification, dose error reduction software and EMR interoperability BD Alaris™ Infusion System's unique "One System" platform securely connects all patient modules to provide care teams with a single, comprehensive patient view B D sales and service teams will begin actively engaging customers on next steps for their infusion devices; Operational capacity investments will enable rapid scale-up of BD Alaris ™ Infusion System to begin distribution and remediation or replacement of existing devices BD does not expect any material incremental revenue contribution from the BD Alaris™ Infusion System for the remainder of FY23; Expects to absorb initial re-launch investments within FY23 guidance range FRANKLIN LAKES, N.J. , July 21, 2023  /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the updated BD Alaris™ Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States.

BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

Company Expands its ESG Focus Areas to Include Advancing Health Equity in Under-Resourced Communities  FRANKLIN LAKES, N.J. , July 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2022 Environmental, Social and Governance (ESG) Report that details ongoing efforts that impact company health, human health, community health and planet health.

BD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity

BD's (BDX) slew of product launches raises optimism about the stock.

Here's Why You Should Add BD (BDX) Stock in Your Portfolio

Apple

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Blackrock Inc

Bristol-Myers

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

Top Score on Disability Equality Index Demonstrates Ongoing Progress in Creating Employment Opportunities for People with Disabilities FRANKLIN LAKES, N.J., July 11, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its recognition as a Best Place to Work for Disability Inclusion for the fifth consecutive year.

BD Recognized as a Best Place to Work for Disability Inclusion

Align Technology

Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Align Technology (ALGN). But which of these two stocks is more attractive to value investors?

BDX or ALGN: Which Is the Better Value Stock Right Now?

FRANKLIN LAKES, N.J. , July 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its third quarter of fiscal year 2023 on Thursday, August 3, 2023.

BD to Announce Financial Results for its Third Quarter of Fiscal 2023

Danaher

General Dynamics

General Motors

Goldman Sachs

Roper Technologies

Wells Fargo

Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so.

The 7 Most Undervalued Blue-Chip Stocks to Buy Now: June 2023

Agilent Technologies

Agree Realty

Ameren

Federal Agricultural

Albemarle

Allstate

Allegion

Air Products and Chemicals

Alexandria Real Estate Equities

Atrion

Broadcom

Axis Capital

Booz Allen Hamilton Hld

Brookfield Asset Management

BancFirst

Baxter

Franklin Resources

Brookfield Renewable Partners

Bank of Nova Scotia

Cadence Bank

Crown Castle International

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of June 25

Becton, Dickinson and Company has seen another year of relative stagnation. Following the spinoff of the Diabetes Care unit, sales and earnings have taken a small setback. Valuations remain full at around 20 times adjusted earnings amidst some leverage still being apparent and with structural growth hard to come by.

Becton, Dickinson and Company: Still Not Very Healthy

STERIS

Becton, Dickinson and Co. (BD) BDX, +0.96% said Tuesday it agreed to sell its surgical instrumentation platform to Steris for STE, +0.04% for $540 million, or about 3.2 times the annual revenue of $170 million for the units included in the deal. Steris said the deal is expected to add to its earnings after it closes by Sept.

Steris paying $540 mln for BD surgical instrument unit

Divestiture Advances BD2025 Strategy to Simplify Portfolio  and Focus on Higher-Growth Markets FRANKLIN LAKES, N.J. , June 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (NYSE: STE) for $540 million.

BD to Sell Surgical Instrumentation Platform to STERIS

The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.

BD's (BDX) Latest Product to Automate Clinical Flow Cytometry

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

BD FACSDuet™ Premium System Leverages Robotics to Automate Sample Preparation for Greater Standardization in Clinical Flow Cytometry Diagnostics FRANKLIN LAKES, N.J. , June 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete "walkaway" workflow solution designed to improve standardization and reproducibility in cellular diagnostics.

BD Launches New Robotic System to Automate Clinical Flow Cytometry

I expect Becton, Dickinson and Company to beat 2H23 estimates due to reduced expectations and margin improvements. BDX's management has made progress in SKU rationalizations, workforce reduction, and enhancing the company's structural margin profile. The stable operating environment, procedure volume recovery, and hospital capital spending appetite support revenue growth for BDX.

Becton, Dickinson: Business Should Beat H2 2023 Expectations

BD PosiFlush™ SafeScrub Streamlines Clinical Workflow for Disinfecting and Flushing IV Catheters to Help Improve Patient Care FRANKLIN LAKES, N.J. , May 23, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced expanded customer availability of an all-in-one prefilled flush syringe with an integrated disinfection unit designed to reinforce compliance to infection prevention guidelines and simplify nursing workflow.

BD Advances Prefilled Flush Syringe with Integrated 'Scrub-the-Hub' Innovation

News for Becton, Dickinson and Co. Stock (BDX)